Targeting CDKs has become a promising strategy in cancer therapy. CDK inhibitors are designed to block the kinase activity of CDKs, thereby halting cell cycle progression and inducing cell death in cancer cells. Several CDK inhibitors have been developed and approved for clinical use. For example, Palbociclib, Ribociclib, and Abemaciclib specifically inhibit CDK4 and CDK6 and are used in the treatment of hormone receptor-positive breast cancer.
